Interestingly, treatment with cabozantinib elicited marked tumour growth delay, but not regression, in neuroblastomas arising in both Th-MYCN and Th-MYCN/ALKF1174L mice, the effect being more pronounced in the Th-MYCN mice. This evidence concerns the gene MYCN and neuroblastoma.